Aurinia Pharmaceuticals Inc $AUPH Shares Bought by Ritholtz Wealth Management

Ritholtz Wealth Management grew its position in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 21.5% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 314,426 shares of the biotechnology company’s stock after acquiring an additional 55,610 shares during the period. Ritholtz Wealth Management owned about 0.24% of Aurinia Pharmaceuticals worth $4,660,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Arrowstreet Capital Limited Partnership grew its position in shares of Aurinia Pharmaceuticals by 213.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,374,021 shares of the biotechnology company’s stock valued at $37,283,000 after acquiring an additional 2,297,903 shares during the period. Marshall Wace LLP raised its holdings in Aurinia Pharmaceuticals by 1,272.5% in the 3rd quarter. Marshall Wace LLP now owns 1,483,132 shares of the biotechnology company’s stock worth $16,389,000 after purchasing an additional 1,375,072 shares during the period. Kotler Kevin purchased a new position in Aurinia Pharmaceuticals during the fourth quarter worth approximately $19,536,000. Two Sigma Investments LP boosted its position in Aurinia Pharmaceuticals by 728.6% during the third quarter. Two Sigma Investments LP now owns 1,341,067 shares of the biotechnology company’s stock worth $14,819,000 after purchasing an additional 1,179,219 shares in the last quarter. Finally, Man Group plc grew its holdings in Aurinia Pharmaceuticals by 368.9% in the fourth quarter. Man Group plc now owns 852,671 shares of the biotechnology company’s stock valued at $13,600,000 after purchasing an additional 670,812 shares during the period. 36.83% of the stock is owned by hedge funds and other institutional investors.

Aurinia Pharmaceuticals Stock Performance

NASDAQ:AUPH opened at $17.55 on Friday. The company has a market cap of $2.26 billion, a P/E ratio of 8.09 and a beta of 1.41. Aurinia Pharmaceuticals Inc has a twelve month low of $7.28 and a twelve month high of $19.25. The company’s 50-day moving average price is $15.95 and its 200-day moving average price is $15.34. The company has a current ratio of 5.55, a quick ratio of 5.01 and a debt-to-equity ratio of 0.08.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.07. The company had revenue of $77.71 million during the quarter, compared to analysts’ expectations of $76.98 million. Aurinia Pharmaceuticals had a net margin of 99.97% and a return on equity of 26.62%. On average, sell-side analysts forecast that Aurinia Pharmaceuticals Inc will post 0.82 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut Aurinia Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, May 15th. Two investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $17.25.

Insider Buying and Selling

In related news, CEO Kevin Tang acquired 343,620 shares of the stock in a transaction on Monday, June 1st. The shares were bought at an average price of $15.28 per share, with a total value of $5,250,513.60. Following the completion of the purchase, the chief executive officer owned 12,838,101 shares of the company’s stock, valued at approximately $196,166,183.28. This represents a 2.75% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders purchased a total of 814,606 shares of company stock worth $12,455,129 in the last quarter. Company insiders own 12.20% of the company’s stock.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.